NetworkNewsBreaks – Tonix Pharmaceuticals Holdin
Post# of 112
(Total Views: 51)
Posted On: 09/18/2024 5:35:49 PM
NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp.’s (NASDAQ: TNXP) TNX-801 Positioned as Viable Contender in Global Fight Against Mpox
Tonix Pharmaceuticals Holding (NASDAQ: TNXP) is a biopharmaceutical company with marketed products and a pipeline of development candidates. Tonix’s TNX-801, a live-virus vaccine candidate, could potentially offer a more viable solution to address the growing global mpox crisis. TNX-801 shows promise because it appears to align with the preferred target product profile (“TPP”) recently issued by the World Health Organization (“WHO”). The TPP emphasizes a well-tolerated, single-dose vaccine that can be administered, shipped and stored in Africa and around the world.
Jynneos(R) and ACAM2000(R), two FDA-approved vaccines for mpox, do not fully meet WHO’s TPP. Thus, TNX-801 potentially offers a much-needed alternative. Preclinical trials of the vaccine candidate showed that it provides single-dose protection against the newly spreading strain of the monkeypox virus called Clade I. Additionally, TNX-801 is suitable for making lyophilized versions that are expected to be stable at ambient temperatures for about 8 hours, helping with logistics in various parts of the world. “Beyond its alignment with WHO’s single-dose requirement, TNX-801 seems to offer multiple competitive features that could position it as a viable contender in the global fight against mpox,” the press release reads.
NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Tonix Pharmaceuticals Holding (NASDAQ: TNXP) is a biopharmaceutical company with marketed products and a pipeline of development candidates. Tonix’s TNX-801, a live-virus vaccine candidate, could potentially offer a more viable solution to address the growing global mpox crisis. TNX-801 shows promise because it appears to align with the preferred target product profile (“TPP”) recently issued by the World Health Organization (“WHO”). The TPP emphasizes a well-tolerated, single-dose vaccine that can be administered, shipped and stored in Africa and around the world.
Jynneos(R) and ACAM2000(R), two FDA-approved vaccines for mpox, do not fully meet WHO’s TPP. Thus, TNX-801 potentially offers a much-needed alternative. Preclinical trials of the vaccine candidate showed that it provides single-dose protection against the newly spreading strain of the monkeypox virus called Clade I. Additionally, TNX-801 is suitable for making lyophilized versions that are expected to be stable at ambient temperatures for about 8 hours, helping with logistics in various parts of the world. “Beyond its alignment with WHO’s single-dose requirement, TNX-801 seems to offer multiple competitive features that could position it as a viable contender in the global fight against mpox,” the press release reads.
NOTE TO INVESTORS: The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Research Links
Scroll down for more posts ▼